Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

image shows hand holding a nasal spray which administers the drug.

In the US, patients who start esketamine ($600 a dose) are asked about whether they have previously taken ketamine ($10 a dose), but not the other way round.

Associate Professor Rupert McShane, University of Oxford, says,

"History teaches us just how important it is to track patients who switch from one potentially addictive drug to another. European and UK regulators urgently need to ensure that treatments with ketamine, and other potentially addictive drugs, are all tracked in the same system along with esketamine. This same logic applies to people who are self-treating without a prescription. This sensible precaution would help prevent esketamine from suffering the same fate as benzodiazepines: overuse, backlash and stigma."

 

Patients' experiences matter – this sort of data platform will give them a voice.Associate Professor Rupert McShane.

 

Read the full article authored by Rupert McShane and Adam Winstock.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

How Mindfulness May Improve Body Satisfaction and Mood

New research from Emma Osborne, Research Assistant at the Centre for Research on Eating Disorders (CREDO) at the University of Oxford (and PhD Candidate at the University of Bath), and Dr Melissa Atkinson, University of Bath, investigated two ways in which mindfulness might improve body satisfaction and mood.

Review Highlights Risk Factors Associated with Violence in Schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

New Study will Investigate Brain Fog Symptoms in Post-Hospitalised COVID-19 Patients

C-Fog is a collaborative new study led by Oxford University researcher, Dr Maxime Taquet, which will investigate the reasons why brain fog or cognition problems affect patients after COVID-19 infection. With a better understanding of the mechanisms involved it may be possible to understand how to treat brain fog and help many thousands of people worldwide.

A New Experimental Study Investigated the Effects of Atorvastatin on Emotional Processing

Atorvastatin is one of a group of statins widely used to treat heart and blood vessel diseases. The medication works by lowering cholesterol in the blood. This new study shows that atorvastatin influences the way people experience certain emotions, giving us important insights about disorders such as anxiety and depression.

People with Long-COVID After Hospitalisation Face Limited Recovery After One Year

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge, according to the latest results of a major national study looking at the long-term health impacts of COVID-19 on hospitalised patients.

The Effects of Social Media on Public Attention and Attitudes Towards COVID-19 Vaccines in the UK

A new study finds that media coverage of positive vaccine research can have a positive effect on overall social media sentiment, countering vaccine misinformation, but the effects wane over time.